DK2125779T3 - Polymorphs A mGluR5 RECEPTOR ANTAGONIST - Google Patents

Polymorphs A mGluR5 RECEPTOR ANTAGONIST Download PDF

Info

Publication number: DK2125779T3
Authority: DK; Denmark
Prior art keywords: fluoro; ylethynyl; chloro; phenyl; dimethyl
Prior art date: 2006-12-21

Application number

DK07857408.4T

Other languages

Danish (da)

English (en)

Inventor

Thomas P Cleary

Alexander Glomme

Olaf Grassmann

Shan-Ming Kuang

Roland Meier

Franziska E Rohrer

Jason Yang

Doreen Miller

Regina Moog

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-21

Filing date

2007-12-11

Publication date

2016-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2125779(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-11 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2016-07-04 Application granted granted Critical

2016-07-04 Publication of DK2125779T3 publication Critical patent/DK2125779T3/en

Links

102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 title description 4
108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 title description 4
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 33
UPZWINBEAHDTLA-UHFFFAOYSA-N basimglurant Chemical compound CC=1N(C=2C=CC(F)=CC=2)C(C)=NC=1C#CC1=CC=NC(Cl)=C1 UPZWINBEAHDTLA-UHFFFAOYSA-N 0.000 claims description 31
150000003839 salts Chemical class 0.000 claims description 27
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 14
238000002441 X-ray diffraction Methods 0.000 claims description 13
230000005855 radiation Effects 0.000 claims description 11
238000002329 infrared spectrum Methods 0.000 claims description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
208000002193 Pain Diseases 0.000 claims description 8
230000001684 chronic effect Effects 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
208000019901 Anxiety disease Diseases 0.000 claims description 4
206010003805 Autism Diseases 0.000 claims description 4
208000020706 Autistic disease Diseases 0.000 claims description 4
208000000094 Chronic Pain Diseases 0.000 claims description 4
206010067125 Liver injury Diseases 0.000 claims description 4
208000012902 Nervous system disease Diseases 0.000 claims description 4
208000025966 Neurological disease Diseases 0.000 claims description 4
208000008589 Obesity Diseases 0.000 claims description 4
206010046543 Urinary incontinence Diseases 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
208000005298 acute pain Diseases 0.000 claims description 4
230000036506 anxiety Effects 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
231100000234 hepatic damage Toxicity 0.000 claims description 4
230000008818 liver damage Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
235000020824 obesity Nutrition 0.000 claims description 4
238000001556 precipitation Methods 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
238000001953 recrystallisation Methods 0.000 claims description 3
230000002269 spontaneous effect Effects 0.000 claims description 3
239000013543 active substance Substances 0.000 claims description 2
229910016523 CuKa Inorganic materials 0.000 claims 3
208000001914 Fragile X syndrome Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000013078 crystal Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
239000000203 mixture Substances 0.000 description 7
238000000634 powder X-ray diffraction Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000002411 thermogravimetry Methods 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000002775 capsule Substances 0.000 description 5
239000010949 copper Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000001828 Gelatine Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
238000000034 method Methods 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000012458 free base Substances 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical group OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000001757 thermogravimetry curve Methods 0.000 description 3
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000000873 masking effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000010899 nucleation Methods 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000004467 single crystal X-ray diffraction Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000000547 structure data Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229910002483 Cu Ka Inorganic materials 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical group [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000013480 data collection Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000010354 integration Effects 0.000 description 1
-1 invert sugar Substances 0.000 description 1
229960004903 invert sugar Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical group FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000010926 purge Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000011003 system suitability test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002834 transmittance Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK07857408.4T 2006-12-21 2007-12-11 Polymorphs A mGluR5 RECEPTOR ANTAGONIST DK2125779T3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87639806P	2006-12-21	2006-12-21
PCT/EP2007/063721 WO2008074697A1 (fr)	2006-12-21	2007-12-11	Polymorphes d'un antagoniste du récepteur mglur5

Publications (1)

Publication Number	Publication Date
DK2125779T3 true DK2125779T3 (en)	2016-07-04

Family

ID=39186951

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07857408.4T DK2125779T3 (en)	2006-12-21	2007-12-11	Polymorphs A mGluR5 RECEPTOR ANTAGONIST

Country Status (32)

Country	Link
US (2)	US8063076B2 (fr)
EP (1)	EP2125779B1 (fr)
JP (1)	JP5405311B2 (fr)
KR (1)	KR101148580B1 (fr)
CN (1)	CN101568531B (fr)
AR (1)	AR064654A1 (fr)
AU (1)	AU2007336369B2 (fr)
CA (1)	CA2673444C (fr)
CL (1)	CL2007003695A1 (fr)
CO (1)	CO6210731A2 (fr)
CY (1)	CY1117810T1 (fr)
DK (1)	DK2125779T3 (fr)
EC (1)	ECSP099431A (fr)
ES (1)	ES2577391T3 (fr)
HR (1)	HRP20160950T1 (fr)
HU (1)	HUE029324T2 (fr)
IL (1)	IL199181A (fr)
MA (1)	MA31008B1 (fr)
MX (1)	MX2009006694A (fr)
MY (1)	MY148217A (fr)
NO (1)	NO342451B1 (fr)
NZ (1)	NZ577440A (fr)
PE (1)	PE20081484A1 (fr)
PL (1)	PL2125779T3 (fr)
PT (1)	PT2125779T (fr)
RS (1)	RS54853B1 (fr)
RU (1)	RU2460728C2 (fr)
SI (1)	SI2125779T1 (fr)
TW (1)	TWI347320B (fr)
UA (1)	UA96970C2 (fr)
WO (1)	WO2008074697A1 (fr)
ZA (1)	ZA200904289B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY148217A (en)	2006-12-21	2013-03-29	Hoffmann La Roche	Polymorphs of a mglur5 receptor antagonist
US20120039999A1 (en) *	2010-08-11	2012-02-16	Ashish Chatterji	Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20140228398A1 (en)	2011-03-18	2014-08-14	Novartis Ag	COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
EP2837631A1 (fr) *	2013-08-14	2015-02-18	Merck & Cie	Nouveau sel stable d'acide 5,10-méthylène-(6R)-tétrahydrofolique
GB201317022D0 (en) *	2013-09-25	2013-11-06	Addex Pharmaceuticals Sa	Polymorphs
EP3092255A4 (fr)	2014-01-10	2017-09-20	Birdie Biopharmaceuticals Inc.	Composés et compositions pour le traitement de tumeurs exprimant egfr
CN115252792A (zh)	2016-01-07	2022-11-01	博笛生物科技有限公司	用于治疗肿瘤的抗-egfr组合
CN118515666A (zh)	2017-04-27	2024-08-20	博笛生物科技有限公司	2-氨基-喹啉衍生物
IL298709A (en) *	2020-06-05	2023-02-01	Noema Pharma Ag	Methods for treating multiple sclerosis complex
CN115989024A (zh) *	2020-07-30	2023-04-18	诺埃玛制药公司	治疗三叉神经痛的方法
CN120459099A (zh) *	2025-06-17	2025-08-12	北京大学成都前沿交叉生物技术研究院	mGlu5抑制剂在治疗或预防非酒精性脂肪肝病和/或肥胖、改善瘦素敏感性方面的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3303199A (en)	1963-07-15	1967-02-07	Geigy Chem Corp	Certain imidazolone derivatives and process for making same
US3341548A (en)	1964-04-29	1967-09-12	Hoffmann La Roche	Nitroimidazoles and their preparation
DE2035905A1 (de)	1970-07-20	1972-02-03	Chemische Fabrik Stockhausen & Cie.,4150Krefeld	Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (fr)	1981-02-27	1984-09-18	Walter Hunkeler	Imidazodiazepines
EP0079312A3 (fr)	1981-11-11	1984-04-25	Ciba-Geigy Ag	Composés d'acétylène hétérocycliques
US4711962A (en)	1984-10-18	1987-12-08	Stauffer Chemical Company	Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
HU217958B (hu)	1989-06-30	2000-05-28	E. I. Du Pont De Nemours And Co.	Helyettesített imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
TW544448B (en)	1997-07-11	2003-08-01	Novartis Ag	Pyridine derivatives
CA2297732C (fr)	1997-08-14	2008-04-29	F. Hoffmann-La Roche Ag	Ethers heterocycliques de vinyle utiles contre des troubles neurologiques
WO2001016121A1 (fr)	1999-08-31	2001-03-08	Merck & Co., Inc.	Composes heterocycliques et procedes d'utilisation de ceux-ci
JP5154728B2 (ja)	2000-07-24	2013-02-27	クレニツキー・ファーマシューティカルズ，インコーポレイテッド	神経栄養活性を有する置換５−アルキニルピリミジン
ATE288898T1 (de)	2000-12-04	2005-02-15	Hoffmann La Roche	Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
US6627646B2 (en) *	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs
EP1458385A4 (fr)	2001-12-19	2005-12-21	Merck & Co Inc	Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5
TWI292318B (en)	2003-03-10	2008-01-11	Hoffmann La Roche	Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) *	2003-06-05	2007-11-12	Hoffmann La Roche	Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en)	2003-07-03	2006-08-15	Hoffmann-La Roche Inc.	Imidazole derivatives
US7452909B2 (en)	2003-09-04	2008-11-18	Hoffman-La Roche Inc.	Imidazole derivatives
PL1756086T3 (pl) *	2004-06-01	2008-11-28	Hoffmann La Roche	Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5
MY148217A (en)	2006-12-21	2013-03-29	Hoffmann La Roche	Polymorphs of a mglur5 receptor antagonist

2007
- 2007-12-11 MY MYPI20092393A patent/MY148217A/en unknown
- 2007-12-11 NZ NZ577440A patent/NZ577440A/en unknown
- 2007-12-11 RU RU2009123135/04A patent/RU2460728C2/ru active
- 2007-12-11 EP EP07857408.4A patent/EP2125779B1/fr active Active
- 2007-12-11 AU AU2007336369A patent/AU2007336369B2/en active Active
- 2007-12-11 MX MX2009006694A patent/MX2009006694A/es active IP Right Grant
- 2007-12-11 UA UAA200907474A patent/UA96970C2/ru unknown
- 2007-12-11 CA CA2673444A patent/CA2673444C/fr active Active
- 2007-12-11 JP JP2009541986A patent/JP5405311B2/ja active Active
- 2007-12-11 CN CN2007800475969A patent/CN101568531B/zh active Active
- 2007-12-11 PL PL07857408.4T patent/PL2125779T3/pl unknown
- 2007-12-11 PT PT78574084T patent/PT2125779T/pt unknown
- 2007-12-11 RS RS20160461A patent/RS54853B1/sr unknown
- 2007-12-11 DK DK07857408.4T patent/DK2125779T3/en active
- 2007-12-11 WO PCT/EP2007/063721 patent/WO2008074697A1/fr not_active Ceased
- 2007-12-11 ES ES07857408.4T patent/ES2577391T3/es active Active
- 2007-12-11 KR KR1020097012810A patent/KR101148580B1/ko active Active
- 2007-12-11 HU HUE07857408A patent/HUE029324T2/en unknown
- 2007-12-11 HR HRP20160950TT patent/HRP20160950T1/hr unknown
- 2007-12-11 SI SI200731792A patent/SI2125779T1/sl unknown
- 2007-12-14 PE PE2007001802A patent/PE20081484A1/es not_active Application Discontinuation
- 2007-12-17 US US11/957,515 patent/US8063076B2/en active Active
- 2007-12-19 TW TW096148786A patent/TWI347320B/zh active
- 2007-12-19 CL CL200703695A patent/CL2007003695A1/es unknown
- 2007-12-21 AR ARP070105822A patent/AR064654A1/es not_active Application Discontinuation
2009
- 2009-06-04 IL IL199181A patent/IL199181A/en active IP Right Grant
- 2009-06-05 CO CO09058653A patent/CO6210731A2/es not_active Application Discontinuation
- 2009-06-15 EC EC2009009431A patent/ECSP099431A/es unknown
- 2009-06-17 MA MA32012A patent/MA31008B1/fr unknown
- 2009-06-18 ZA ZA200904289A patent/ZA200904289B/xx unknown
- 2009-06-19 NO NO20092357A patent/NO342451B1/no unknown
2011
- 2011-10-14 US US13/273,266 patent/US8329912B2/en active Active
2016
- 2016-07-19 CY CY20161100705T patent/CY1117810T1/el unknown

Also Published As

Publication number	Publication date
ECSP099431A (es)	2009-07-31
RU2460728C2 (ru)	2012-09-10
MA31008B1 (fr)	2009-12-01
CN101568531A (zh)	2009-10-28
ES2577391T3 (es)	2016-07-14
RU2009123135A (ru)	2011-01-27
SI2125779T1 (sl)	2016-07-29
EP2125779B1 (fr)	2016-04-27
AR064654A1 (es)	2009-04-15
PL2125779T3 (pl)	2016-11-30
TW200833679A (en)	2008-08-16
NO342451B1 (no)	2018-05-22
AU2007336369A1 (en)	2008-06-26
KR101148580B1 (ko)	2012-05-24
NO20092357L (no)	2009-07-15
NZ577440A (en)	2011-12-22
BRPI0720954A2 (pt)	2014-03-18
PE20081484A1 (es)	2008-10-18
WO2008074697A1 (fr)	2008-06-26
CN101568531B (zh)	2013-11-13
US20080312288A1 (en)	2008-12-18
EP2125779A1 (fr)	2009-12-02
UA96970C2 (en)	2011-12-26
HUE029324T2 (en)	2017-02-28
CA2673444C (fr)	2015-01-20
CL2007003695A1 (es)	2008-07-04
PT2125779T (pt)	2016-07-19
TWI347320B (en)	2011-08-21
AU2007336369B2 (en)	2013-01-17
JP2010513378A (ja)	2010-04-30
CO6210731A2 (es)	2010-10-20
US8329912B2 (en)	2012-12-11
RS54853B1 (sr)	2016-10-31
HRP20160950T1 (hr)	2016-10-07
CA2673444A1 (fr)	2008-06-26
MY148217A (en)	2013-03-29
US20120035222A1 (en)	2012-02-09
IL199181A (en)	2016-02-29
US8063076B2 (en)	2011-11-22
JP5405311B2 (ja)	2014-02-05
KR20090081026A (ko)	2009-07-27
ZA200904289B (en)	2010-04-28
CY1117810T1 (el)	2017-05-17
MX2009006694A (es)	2009-06-30

Publication	Publication Date	Title
EP2125779B1 (fr)	2016-04-27	Polymorphes d'un antagoniste du récepteur mglur5
DK2114405T3 (en)	2015-04-07	Methylparaben cokrystallinsk form "A" of [4- (3-fluoro-5-trifluoromethyl-pyridin-2-yl) -piperazin-l-yl] - [5-methanesulfonyl-2 - ((S) -2,2,2 trifluoro-1-methyl-ethoxy) -phenyl] -methanone
CZ2002404A3 (cs)	2002-06-12	Polymorfní formy torsemidu
CN114401720A (zh)	2022-04-26	多酪氨酸激酶抑制剂的晶型、制备方法及其用途
BRPI0720954B1 (pt)	2025-02-04	Forma cristalina do sal de monossulfato de um antagonista de receptor mglur5, seu uso, processo de preparação do mesmo e composição farmacêutica que o compreende